Evidence map›Paper›PMID 40483295›Full record

ArticleEuropean radiology2025

Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [

Shaopeng Li, Junhan Wu, Zijie Li, Haijie Xu, Weitao Zhuang, Yong Tang, Xin Xia, Zhe He, Zihua Lan, Aotian Mo and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shaopeng Li *Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Junhan Wu *Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Zijie Li *Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Haijie XuShantou University Medical College, Shantou, China.
Weitao ZhuangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yong TangDepartment of Thoracic Surgery, Shenzhen Nanshan People's Hospital, Shenzhen, China.
Xin XiaDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Zhe HeDepartment of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zihua LanShantou University Medical College, Shantou, China.
Aotian MoDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Yizhang ChenDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Weifeng ZhongDepartment of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Rixin ChenResearch Center of Medical Sciences, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. chenrixin@gdph.org.cn.
Guibin QiaoDepartment of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China. guibinqiao@126.com.ORCID http://orcid.org/0000-0001-9200-9317

Funding

Natural Science Foundation of Guangdong Province, Chin 2022A1515110399, 2024A1515012860the National Key R&D Program of China 2022YFE0133100
6 · The paper itself

Abstract

objectivesAccurately predicting the pathological response of lymph nodes to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC) remains a challenge. This study aimed to evaluate the effectiveness of [ MATERIALS AND

methodsA total of 86 patients with stage IIB-IIIB NSCLC were enrolled. [

resultsThe metabolism composite index, which combines changes in SUVmax of the primary tumor and post-treatment SUVmax of lymph nodes, significantly improved lymph node response prediction, with an AUC of 0.852 (95% CI: 0.772, 0.932), sensitivity of 0.783, and specificity of 0.811. Patients without a pathological complete response (pCR) had shorter median EFS in the non-pCR/PET (N+) group compared to the non-pCR/PET (N-) group (17 months vs 42 months, p < 0.001).

conclusionIntegrating dynamic metabolic changes in the primary tumor with post-treatment lymph node metabolic status is highly effective in predicting lymph node response to neoadjuvant chemoimmunotherapy. This method also helps identify patients with less favorable prognoses within the non-pCR group. KEY POINTS: Question How effective is [

Indexed as

Carcinoma, Non-Small-Cell LungFluorodeoxyglucose F18ImmunotherapyLung NeoplasmsLymph NodesPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPredictive Value of TestsFluorodeoxyglucose F18Radiopharmaceuticals[18F]FDG PET/CTLymph node responseNeoadjuvant chemoimmunotherapyNon-small cell lung cancer

Identifiers

PMID40483295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.